poisar

Stock

Palisade Bio, Inc. PALI

$1.95-3.23%

Overview

PALI market data

Price History

PALI price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$10.19
Diluted earnings per share over the trailing twelve months.
Beta
1.44
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.53 – $2.86
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $346.9 · P/B 2.71 · P/S 1,387.67.

Company news

10 captured
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative ColitisBenzinga · Jul 23, 2026, 6:06 PM
Palisade Bio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $8 price target.Benzinga · Jul 23, 2026, 3:21 PM
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jul 23, 2026, 11:29 AM
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8Benzinga · Jul 23, 2026, 10:57 AM
Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative ColitisBenzinga · Jun 29, 2026, 12:40 PM
8-K filing — PALISADE BIO, INC. (PALI)SEC EDGAR · Jun 11, 2026, 9:23 PM
Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis SymposiumBenzinga · Jun 9, 2026, 12:50 PM
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga · May 27, 2026, 12:02 PM
Palisade Bio Files Prospectus To Offer And Sell Up To $300M Of SecuritiesBenzinga · May 12, 2026, 9:35 PM
Palisade Bio Q1 EPS $(0.05) Misses $(0.04) EstimateBenzinga · May 12, 2026, 8:30 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock